Sodium-glucose transport protein 2 inhibitor use in diabetes and its association with tuberculosis incidence.

ABSTRACT:

Background

Sodium-glucose cotransporter 2 inhibitors (SGLT2i) are increasingly prescribed in diabetes mellitus (DM) patients, yet their impact on tuberculosis (TB) incidence remains unclear. This study analyzed TB risk in DM patients with and without SGLT2i use.

Methods

We conducted a retrospective cohort study using data from the Taiwan National Health Insurance Research Database between 2017 to 2020. DM patients treated with or without SGLT2i were identified, and propensity score (PS) matching was performed to balance baseline characteristics, including age, sex, comorbidities, and Diabetes Complications Severity Index (DCSI) between these two groups. TB incidence was assessed until December 31, 2021, and compared between groups. To consider death as a competing risk, a Co

SUBMITTER: Liu CJ 

PROVIDER: S-EPMC12625201 | biostudies-literature | 2025 Nov

REPOSITORIES: biostudies-literature